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Apoptosis signal-regulating kinase 
1 mediates striatal degeneration 
via the regulation of C1q
Kyoung Joo Cho1, So Young Cheon2 & Gyung Whan Kim1
Apoptosis signal-regulating kinase-1 (ASK1), an early signaling element in the cell death pathway, 
has been hypothesized to participate in the pathology of neurodegenerative diseases. The systemic 
administration of 3-nitropropionic acid (3-NP) facilitates the development of selective striatal lesions. 
However, it remains unclear whether specific neurons are selectively targeted in 3-NP-infused striatal 
degeneration. Recently, it has been proposed that complement-mediated synapse elimination may be 
reactivated aberrantly in the pathology of neurodegenerative diseases. We hypothesized that ASK1 is 
involved in striatal astrocyte reactivation; reactive astrocyte secretes molecules detrimental to neuron; 
and striatal neurons are more susceptible to these factors. Our results indicate that striatal astrocyte is 
reactivated and ASK1 level increases after 3-NP general and chronic infusion. Reactive striatal astrocyte 
increases TGF-beta differentially to cortex and striatum. ASK1 may be involved in regulation of 
astrocyte TGF-beta and it is linked to the C1q level in spatial and temporal, and moreover in the earlier 
stage of progressing striatal neuronal loss. Conclusively the present study suggests that ASK1 mediates 
3-NP toxicity and regulates C1q level through the astrocyte TGF-beta. And also it may suggest that C1q 
level may be a surrogate of prediction marker representing neurodegenerative disease progress before 
developing behavioral impairment.
The systemic administration of 3-nitropropionic acid (3-NP) facilitates the development of selective striatal lesions. 
However, it remains unclear whether specific neurons are selectively targeted in 3-NP-infused striatal degener-
ation. It is well known that 3-NP inhibits succinate dehydrogenase (SDH) and mitochondrial complex II to the 
same extent in the cerebrum and striatum1,2, which suggest that 3-NP neurotoxicity is similar in the cerebrum and 
striatum. 3-NP-induced neurotoxicity has been shown to have the following effects: the exhaustion of adenosine 
triphosphate, mitochondrial membrane depolarization, dysregulation of intracellular calcium homeostasis, calpain 
activation, and the release of pro-apoptotic proteins from the mitochondria3–5. The neurotoxic mechanism and the 
reason for the selective vulnerability of the striatum are not yet well understood. Therefore, the molecular mech-
anisms underlying 3-NP-induced striatal lesions remain to be fully defined6. As a crucial component of neuronal 
loss in neurodegenerative disease, innate immune cascade is emerging7. C1q is a component of the complement 
initiator C1 complex. Excess C1q may lead to an increase in functionally active levels of C1, which results in an 
increase in the activation of the classical complement pathway8. During development, C1q is expressed in the 
synaptic regions of the developing postnatal central nervous system (CNS)9. Based on the brain developmental 
stage, the complement pathway can trigger either appropriate neuronal development or chronic inflammation, 
the latter of which is involved in neurodegeneration9. The overexpression of C1q in the CNS has been observed 
in several injury models10. In a stroke model, an increase in C1q drives two independent pathophysiological 
mechanisms involved in the processes of lesion formation and blood-brain barrier (BBB) disruption11. C1q plays 
a role as a pattern recognition receptor12 that mediates the clearance of cells undergoing cell death by apoptosis13 
and can enhance the uptake of apoptotic cells14. Exogenous plasma C1q, therefore, may play a role in the initia-
tion of cell activation in microglial cells during the course of CNS diseases that involve BBB impairment and may 
contribute in an autocrine or paracrine way to maintain and balance microglial activation in the diseased CNS 
tissue15. Neuronal C1q expression is downregulated in the CNS in adulthood16, but knock-out mice lacking C1q 
have sustained defects in CNS synapse elimination17.
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Apoptosis signal-regulating kinase-1 (ASK1), an early signaling element in the cell death pathway18, is activated 
by reactive oxygen species (ROS)19 and is required for ROS-induced apoptosis20. Previous studies have indicated 
that increased levels of activated ASK1 impact the presentation of neurodegenerative diseases21. The rationale for 
targeting ASK1 was based on findings that oxidative stress is causally related to apoptotic neuronal cell death in 
neurodegenerative lesions associated with abnormal protein fragments and aggregates22,23. Although many inves-
tigations have shown that ASK1 is essentially involved in neuronal cell death triggered by various external injuries 
and expanded polyglutamine, the relationship between ASK1 and selective striatal degeneration involving innate 
immunity by the chronic and systemic infusion of 3-NP in mice remains to be elucidated.
Based on the reports mentioned above9,13,17, we assumed as following: when the brain is mildly and chronically 
exposed to mitochondrial toxins, presynaptic neurons degrade first, and the postsynaptic striatal medium spiny 
neurons (MSNs) subsequently wither. Accordingly the current study investigated whether increased levels of ASK1 
triggered by the mild and chronic infusion of 3-NP modulate neuronal C1q secretion and synapse elimination in 
the cortex and striatum. In addition, the current study investigated the involvement of astrocyte-derived TGF-beta 
as an inducing factor for C1q in neurodegenerative striatal cell death.
Results
Selective striatal lesions are formed by the systemic infusion of 3-NP in mice. The histological 
evaluation of 3-NP-infused mice (n = 11 each) revealed scant striatal lesions at day four but significant selec-
tive striatal cell loss at day seven (Fig. 1A). Immunostaining with dopamine- and cyclic adenosine monophos-
phate-regulated phosphoprotein (DARPP32), an established striatal neuron marker, revealed that striatal neurons 
stained with DARPP32 disappeared by day seven (Fig. 1A). Most of the mice exhibited the obvious symptoms 
of selective striatal loss, such as weight loss and severe motor dysfunction, seven days after systemic 3-NP infu-
sion. The motor function was tested whether the mice were able to adjust to imbalanced postural challenges. 
Mice infused with 3-NP did not display any neurological deficits until day four. Five days later, however, hind-
limb clasping was observed (Fig. 1B) and an adjustment to postural imbalances was failed. On rotarod test, the 
3-NP-infusion mice could not remain on the rotarod and body weight was reduced to 70% of the initial weight 
(Fig. 1B, n = 12 each). The DNA damage in the brain was determined by TUNEL staining at day seven (Fig. 1C, 
n = 6 each). Apoptotic cell death assay present the quantitative values in each region of cortex and striatum, and 
Figure 1. The chronic infusion of 3-NP induces cell death and selective striatal lesions. (A) Histological 
analysis by cresyl violet staining demonstrates selective striatal cell loss at day seven (upper). Striatal neurons 
stained by DARPP32 are almost undetectable by day seven (lower). (B) Mice exhibited hindlimb impairment on 
day seven (upper). The body weight of 3-NP infused mice decreased gradually (lower, left graph), and mice had 
trouble staying on the rotarod (lower, right graph). (C) Cell death assay present the quantitative values in each 
region of cortex and striatum. (D) Western blot analyses of ASK1 and pASK1 (Thr845, active ASK1) indicate 
the activation of ASK1 in the cortex following 3-NP chronic infusion. The protein level of ASK1 and pASK1 are 
shown in the quantified graphs. *p < 0.05; Scale bars: 2 mm, 500 μ m, and 100 μ m.
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it increased over the days following 3-NP infusion (Fig. 1C). To evaluate primary response to damage by 3-NP, 
both ASK1 and the pASK1 (Thr845, active ASK1), which are found in the MAP kinase pathway, were analyzed 
by Western blot (Fig. 1D, n = 6 each). The amounts of ASK1 and pASK1were greater in 3-NP-infused mice than 
normal, and was also present in higher concentrations in the cortex than the striatum in 3-NP-infused mice. The 
quantified graphs represent normalizing values with ASKl protein amounts.
The infusion of 3-NP leads to selective striatal neuronal loss and also astrocyte reactiva-
tion. Neurons stained with NeuN were distributed homogeneously in the cortex and striatum of control 
animals, whereas sparse neuronal staining was observed in the striatum of 3-NP-infused mice (Fig. 2A, left). 
Moreover, the neuronal loss was more severe in the striatum than in the cortex seven days after 3-NP infusion. 
GFAP immunostaining revealed that astrocytes were weakly detected along the cortex and striatum of normal 
but strongly reactivated in the lateral striatum of 3-NP-infused mice at the boundary between the striatum and 
cortex from the four days after 3-NP infusion (Fig. 2A, right). Our preliminary data in another study indicated 
that C1q, a complement factor in the innate immune system, is elevated by brain injury relating to ASK1 expres-
sion level (data not shown). ELISA revealed that C1q peaked four days after 3-NP infusion before the lesions were 
detectable and were reduced by day seven when the lesions were detectable (Fig. 2B). As a candidate for direct 
factors involving in the regulation of C1q induction, striatal-specific astrocyte reactivation gave hints that an 
astrocyte-related secreting molecule may be involved in selective striatal lesion formation followed by neuronal 
factors that impose neuronal loss or degeneration. We assayed TGF-β 1 secretion level that is the potential factor 
of astrocyte-derived molecules in neuronal loss (Fig. 2C). The secretion levels of TGF-β 1 demonstrated a similar 
temporal pattern to those of C1q, with a higher level on four days after 3-NP infusion than on day seven. It pre-
sented the same pattern with the C1q secreting pattern and it was preceded to definite lesion formation (Fig. 2B).
The downregulation of ASK1 prevented 3-NP-induced cell death and subsequently improved 
neurologic impairment. The ASK1 gene was silenced using siRNA for seven days during 3-NP infu-
sion. Primarily the silencing of the ASK1 gene via siRNA administration was sufficient to downregulate ASK1 
protein levels, which resulted in the inhibition of pASK1 (Thr845) expression (Fig. 3A, n = 7 each). In vivo 
MRIs of siRNA-ASK1-treated 3-NP-infused mice were performed seven days after the infusion of 3-NP and 
siRNA (Fig. 3B, n = 4 each). Progressive enlargement was evident in the lateral ventricles on the contralateral 
side, and striatal atrophy was detected. In contrast, on the ipsilateral side where siRNA-ASK1 was infused, 
ventricular enlargement and striatal atrophy did not indicate severe regression (Fig. 3B). Apoptotic cell death 
assay showed that a lower incidence of cell death was detected in the siRNA-ASK1-treated mice than in the 
siRNA-control-treated mice (data not shown). Consequently, 3-NP-infused mice that received siRNA-ASK1 
treatment were able to remain longer on the rotarod than 3-NP-infused siRNA-control-treated mice (Fig. 3C, 
n = 7 each). The downregulation of ASK1 hampered C1q secretion in the whole blood serum (Fig. 3D, n = 5 
each). With cortical and striatal tissue lysates from si-RNA-con and siRNA-ASK1 treated mice, C1q secreting 
level was also assayed via ELISA. The total level reduced in ASK1 downregulated mice, and it indicated con-
siderable reduction of the C1q level in cortical tissue (Fig. 3E, n = 5 each). To confirm special distribution of 
C1q, C1qR immunohistochemistry was performed in control, 3-NP-infused, ASK1- downregulated. And it was 
confirm whether increased C1q leads C1qR and neuronal loss, C1q was treated into striatum of mice. Several 
C1qR-positive cells were detected in the brains of C1q-treated, and also in four-day-3-NP-infusion mice, which 
Figure 2. The infusion of 3-NP leads to selective striatal neuronal loss as well as astrocyte reactivation.  
(A) Neuronal loss was detected by NeuN Immunostaining (left). Astrocytes were strongly reactivated in the 
lateral striatum as observed by GFAP Immunostaining (right). Reactive astrocytes started to increase from day 
four when the lesion was not yet detected and remained reactivated at day seven when the lesion was definite. 
Each of the two types of CNS cells responded differently to the 3-NP infusion. (B) The ELISA results from 
3-NP-infused mouse blood serum revealed that the secretion levels of C1q were increased on day four when the 
lesion was not yet detectable and on day seven when the lesion was detectable in 3-NP infused mice. (C) The 
results of ELISA for TGF-beta show the similar pattern to that of C1q in 3-NP infused mice. Scale bars: 2 mm 
and 100 μ m.
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was consistent with the findings of elevated C1q secretion (Fig. 4). Few C1qR-positive cells were detected in the 
brains of ASK1-downregulated 3-NP-infused mice.
Astrocyte-secreted TGF-β1 triggers neuronal C1q and degeneration of neuronal dendrites 
mediated by ASK1. To further evaluate the effect of TGF-β 1 on neurons, astrocytes and primary neurons 
were exposed to chronic and mild 3-NP for intoxication (1 mM). The ASK1 protein was increased both in astro-
cytes and neurons following 4 h and 24 h exposures to 3-NP (Fig. 5A). TGF-β 1 mRNA expression was evaluated 
in astrocytes and primary neurons using qPCR (Fig. 5B). Astrocytes and neurons exposed to 3-NP exhibited an 
increase in the expression of TGF-β 1. ELISA revealed that TGF-β 1 secretion increased in response to 3-NP with 
higher levels observed during the 4 h than the 24 h exposure (Fig. 5C). To evaluate whether TGF-β 1 in ACM can 
induce C1q form neuron, astrocyte-conditioned media (ACM) was prepared after for 4 h and 24 h exposure to 
3-NP. The neuron was replaced by prepared ACM and then incubated for another 4 h. The qPCR results revealed 
that neuronal C1q transcripts were highly expressed under ACM. However, when ASK1 was downregulated in 
the neuron, neuronal C1q transcripts were decreased even under ACM (Fig. 5D). Under ACM for 4 h, the C1q 
of the neuron was induced whereas neuronal C1q did not sufficiently trigger under ACM neutralizing TGF-β 1 
(Fig. 5E). Furthermore, when ASK1 was downregulated in the neuron, neuronal C1q transcripts decreased even 
under the ACM containing TGF-β 1. When the neurons were replaced by ACM containing TGF-β 1 for 4 h, neu-
ronal cell death was not detected, but some detrimental changes of the neuronal dendrites were observed by 
anti-PSD95 immunostaining (Fig. 5F).
The distribution of secreted C1q and TGF-β1 are differently regulated to the region. We assayed 
TGF-β 1 secretion level that is the potential factor of astrocyte-derived molecules in neuronal loss (Fig. 2A). 
The secretion levels of TGF-β 1 demonstrated a similar temporal pattern to those of C1q, with a higher level 
on four days after 3-NP infusion than on day seven. The downregulation of ASK1 reduced the levels of TGF-β 1 
secretion (Fig. 6A). The qPCR results to evaluate the regional and temporal expression pattern indicated that 
the mRNA level expressed more in the striatum than the cortex. TGF-β 1 transcript highly increased from day 
four in striatum while cortical TGF-β 1 transcript was considerably increased only at day 7. Moreover it showed 
Figure 3. The downregulation of ASK1 prevents 3-NP-induced striatal cell loss and alleviates motor 
function. (A) pASK1 (Thr845) levels decreased as levels of pAkt (Ser473) increased, which indicates that the 
ASK1 gene was silenced. The semi-quantitative graph shows these results. (B) Representative MRIs display 
diffusion images across seven days of 3-NP-infused mice. ASK1 downregulation was achieved by infusing 
siRNA-ASK1 into one side of the striatum. Each MR image presents the three different positions from the 
bregma. A quantitative analysis was conducted to evaluate the area of the lateral ventricle, and is shown in the 
graph. (C) ASK1 gene-silenced 3-NP-infused mice demonstrated improved motor function on the rotarod 
test. (D) The result of ELISA presents C1q secretion level to be reduced by ASK1 silencing in the mouse whole 
serum infused 3-NP for four days. (E) Real time PCR revealed that the C1q transcripts increased in the cortex 
at day four after 3-NP infusion and significantly decreased by si-ASK1 treatment. Scale bars: 100 μ m and 20 μ m 
each. si-ASK1, siRNA for ASK1; si-control, siRNA for non-functional mixed gene; or, normal; cor, cortex; str, 
striatum; NS, not significant. *p < 0.05.
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that down-regulating ASK1 did not lower TGF-β 1 transcript at least (Fig. 6B). Nevertheless, down-regulating 
ASK1 showed neuroprotective effect in striatal neuron. In addition, the downregulation of ASK1 reduced the 
levels of TGF-β 1 secretion more in the striatum than the cortex in 3-NP infused mice for four days (Fig. 6C). 
Correspondingly, the downregulation of ASK1 hampered C1q secretion in the whole blood serum (Fig. 3D). In 
each cortical and striatal tissue lysates, C1q was also assayed with ELISA indicating the pattern corresponding to 
the TGF-β 1 (Fig. 6D). Overall, these results demonstrate that the downregulation of ASK1 reduces both secretion 
level of TGF-β 1 in astrocyte and C1q in neuron. Moreover, these changes were proceeding to definitely form 
lesion. It could be a good prediction marker if these molecular changes are detected in the neurodegenerative 
disease HD which has character as a selective striatal lesion. Confirmatively, the result of ELISA presented the 
secreted C1q to raise at 8-week-age the early onset stage, and then decline the level at 12-week-age the disease 
developed stage (Fig. 6E). After confirming the Clq level according to disease developing stage, we evaluated 
what the mRNA of ASK1, TGF-β 1, and C1q is expressed between cortex and striatum of HD tg mice at the age of 
10-week. All three kinds of molecules are more expressed in the cortex than the striatum (Fig. 6F).
Discussion
Our previous results suggested that changes in the levels of ASK1 may underlie the differential vulnerability of 
striatal neurons to 3-NP infusion24 or HD25. The 3-NP infusion mouse model was used in this study because a treat-
ment could be concomitantly added at the beginning of pathogenesis. The results of the present study investigated 
whether innate immune factor, regarding as an important factor in neurodegenerative diseases7, participates in 
apoptotic cell clearance and weak synapse elimination in the 3-NP induced selective striatal lesion. Our findings 
are mainly that ASK1 is an initial participant in the pathogenesis of striatal neurodegeneration by 3-NP infusion 
and a crucial applicant in the formation of selective striatal lesions. The results of the present study is (1) chronic 
exposure to 3-NP secreted C1q differentially in each cortex and striatum, which was modulated by differentially 
expressed TGF-beta from astrocytes in each cortex and striatum; and (2) consequently selective striatal degener-
ation was occurred by ASK1 regulating C1q levels via astrocyte-derived TGF-β 1during the early stages of lesion 
formation by chronic 3-NP infusion.
Although the systemic administration of 3-NP causes selective degeneration of neurons in the lateral striatum, 
few studies have infused 3-NP into mice using a subcutaneous osmotic pump, which differs from previous studies 
on rats2,3,26. The chronic systemic administration of 3-NP in rats and non-human primates homogeneously inhibit 
Figure 4. The downregulation of ASK1 restrains C1qR expression. C1qR immunohistochemistry was 
conducted in the cortex and striatum of 3-NP-infused mice. C1qR-positive cells were detected (red dots) four 
and seven days after 3-NP infusion. C1qR immunohistochemistry also was performed in ASK1-downregulated 
and C1q-treated 3-NP-infused mice. Scale bar: 20 μ m.
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the succinate dehydrogenase (SDH) within the brain not solely the striatum3,27. And it is presented in this present 
animal model (Fig. 1). The evident striatal degeneration is occurred, which is associated with behavioral abnor-
malities that are reminiscent of HD, neurodegenerative disease28–30. In the current study, systemic 3-NP infusion 
was followed by increase in ASK1 protein and its active form levels in cortical region in spite of the lesion forming 
in striatal region (Fig. 1). The silencing of the ASK1 gene ameliorated striatal atrophy in the ipsilateral side infused 
with siRNA, as observed by MRI; eventually, motor function also was improved (Fig. 3).
During chronic and mild insults, the sustained exposure of neurons to immune mediators can bring neuronal 
dysfunction and contribute to cell death. Our preliminary data indicated that the transcriptional level of C1q is 
differentially changed by some brain injuries. When the brain is mildly and chronically exposed to 3-NP, C1q 
levels was upregulated in the serum. Moreover, the level was higher in the early stage than the late stage of striatal 
degeneration (Fig. 2). C1q, a complement factor in the classical innate immune pathway, and the dysregulation of 
complement proteins and cytokines has been demonstrated in many CNS disorders, including epilepsy31,32 and 
neurodegenerative diseases33–35. It has been proposed that C1q binds to weaker synapses and tags them for elimina-
tion16. Corresponding to the striatal loss occurring spot, astrocytes were strongly reactivated in the lateral striatum. 
It brought us to explore the astrocyte and the relationship between astrocyte and neuron. Although the signals 
controlling C1q expression and function remain elusive, it is reported that an unidentified secreting signals from 
Figure 5. TGF-beta is differentially expressed in brain subregions, and astrocyte-derived TGF-β1 by 3-NP 
involves ASK1. (A) ASK1 protein levels were evaluated by Western blot in astrocytes (C8D1A) and primary 
neurons exposed to 1 mM 3-NP for 4 h and 24 h. (B) The transcriptional profile of TGF-beta was measured 
by qPCR in the astrocytes and primary neurons. (C) TGF-β 1 secretion levels were assayed in the astrocyte by 
ELISA in a concentrated culture supernatant. The downregulation of ASK1 did not lower the levels of TGF-beta 
transcripts. (D) Neuronal C1q transcripts were highly expressed following 3-NP exposure, and the levels of 
C1q were reduced by ASK1downregulation. (E) Astrocyte-conditioned media (ACM) containing TGF-β 1 can 
affect neuron cytotoxicity. When the neuron was replaced by prepared ACM and then incubated for another 4 h, 
neuronal C1q transcripts were highly expressed. However, ACM neutralized with the TGF-β 1 antibody did not 
trigger an increase in C1q transcriptional levels. (F) When neuronal media were replaced by ACM, changes in 
the neuronal dendrites were demonstrated by immunocytochemistry with anti-PSD95. Scale bar: 5 μ m.
www.nature.com/scientificreports/
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Figure 6. The levels of C1q and TGF-β1 change in response to 3-NP infusion. (A) The secretion level of 
TGF-β 1 was also assessed by ELISA in 3-NP-infused mouse blood serum. TGF-beta was secreted at higher 
levels on day four than on day seven. When ASK1 was downregulated, TGF-β 1 secretion was significantly 
decreased. (B) The transcripts of TGF-beta evaluated by qPCR shows TGF-beta of striatum to increase more 
than cortex. ASK1 downregulating did not affect to reduce the TGF-beta transcripts. (C) The ELISA results 
from 3-NP-infused for four days mouse brain tissue revealed that TGF-β 1 increased on day four and remained 
elevated at a reduced level on day seven. The levels of TGF-β 1 were higher in the striatum than in the cortex. 
The downregulation of ASK1 reduced TGF-beta levels in both the striatum and cortex. (D) The ELISA results 
from 3-NP-infused mouse brain tissue revealed that C1q was increased on day four and remained elevated at a 
reduced level on day seven. The C1q level was evaluated by ELISA separately in the striatum and cortex. ELISA 
also was used to assess C1q in the group of mice that received striatal C1q treatment as well as the group of 
3-NP-infused mice in which ASK1 was downregulated. (E) In R6/2 HD tg mice, the secreting C1q level shows 
to rise in 8 weeks old and 12 weeks old HD tg . (F) The relative levels of transcripts of ASK1, TGF-beta, and C1q 
were measured by qPCR in R6/2 mice (10-week-old). The three kinds of transcript were differentially regulated 
in striatum and cortex. *p < 0.05.
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reactive astrocytes upregulate expression of C1q in neurons. The very recent study reported that retinal TGF-beta 
as a key regulator of neuronal C1q expression and synaptic pruning in the developing visual system36. C1q is rapidly 
upregulated by astrocytic TGF-β 1, and TGF-β 1 is essential to that upregulation. The control of the C1q levels by 
TGF-β 1 is decisive and specific in retinal development and eye-segregation37. We put the hypothesis on as (1) ASK1 
is involved in striatal astrocyte reactivation; (2) reactive astrocyte secretes molecules detrimental to neuron; and 
(3) Striatal neurons are more susceptible to these factors. It is also consistent to our hypothesis that TGF-beta secre-
tion level increased to similar pattern of C1q level (Fig. 2). Our results from C1qR immune-staining in the mouse 
brain revealed the local distribution of C1q (Fig. 4). The downregulation of ASK1 reduced C1qR-positive cells 
in the striatum compared with an increase in the C1q-treated brain. The 3-NP profile appears to be substantially 
attributable to astrocytosis, which is a common component of HD but is not HD-specific or necessarily a significant 
feature of early HD38. Our results also demonstrated that astrocytes were highly reactive in the lateral striatum 
for seven days following the infusion with 3-NP (Fig. 2). We proposed that ASK1 may differentially regulate C1q 
secretion levels via active astrocyte-derived TGF-β 1 in the cortex and striatum, and is consequently involved in 
the axonal degeneration of corticostriatal projection neurons and subsequent striatal dendritic withering.
We supposed that striatal lesion formation results from the non-autonomous events as described above. In a 
previous study that examined TGF-beta signaling, serine-threonine kinase receptor-associated protein (STRAP), 
which is identified as an interacting partner of ASK1, was proposed to interact with TGF-β 1 receptors and 
block TGF-β 1 signaling39. ASK1 phosphorylated STRAP, and the inhibition of ASK1 suppressed the hydroxyl 
peroxide-induced apoptosis mediating STRAP by directly interacting between ASK1 and STRAP. The regulatory 
role of ASK1 in C1q levels may be consistent with this report that ASK1 is working as a negative regulator of the 
STRAP activation of TGF-β 1 signaling. GFAP-positive astrocytes are distributed in the neonatal brain with a 
similar regional heterogeneity. Although the GFAP-positive astrocytes exhibited a different pattern during the 
developmental period and did not disappear at the postnatal stage, the regional allocation of reactive astrocytes 
may be induced by injury37. In the current study, TGF-beta exhibited a similar pattern to C1q on the days follow-
ing 3-NP infusion. Although the downregulation of ASK1 did not reduce astrocytic TGF-β 1 transcription levels 
(data not shown), the secretion level of TGF-β 1 was effectively regulated by ASK1 (Fig. 6). Although it is needed 
the further study, the qPCR with brain tissue and ELISA with whole blood serum were assessed to differentially 
expressing pattern in cortex and striatum each (Fig. 6). It is implicated that the change of C1q level is applying to 
HD moreover could be representing the disease progress.
During chronic infusion of 3-NP, the sustained exposure can weaken neuron synapses, leading to neuronal 
dysfunction and finally striatal neuronal cell death. In the striatal neurodegeneration derived by 3-NP infusion, 
the C1q level is increased at a relatively early stage of degeneration before the lesion or abnormal dysfunction is 
observed. Therefore, the results of the present study suggest that the C1q level in the blood may be a surrogate 
prediction marker representing disease progression, such as in HD. It can be used for prognostic purpose for the 
development of behavioral symptoms or cognitive impairment.
Materials and Methods
Primary neuronal cell culture. Primary neurons were cultured with mouse pups and culture procedures 
are based on the widely used, non-feeder layer–based protocol. Embryonic day 14 pups were removed from the 
pregnant mother mouse. Cortex and striatum was dissected in Hank’s buffered salt solution (CMF-HBSS) and tis-
sues were digested. The supernatant was removed, rinsed with three successive washes of HBSS and resuspended 
in neurobasal media (NB, Life Technologies, USA) contained 0.2 mM GlutaMAX (Life Technologies, USA) and 
2.0% B-27 Supplement (Invitrogen, USA). Cells were subsequently plated on multi-well plates or dish pre-coated 
with 1 mg/mL poly-L-lysine (Sigma, Milwaukee, WI, USA) at a density of 5 × 104 cells per mL. Neurons were 
subsequently incubated at 37 °C with 5% CO2 and remained in culture for 15 days in vitro (DIV). Every 3–4 days, 
the neurons were fed by replacing one half of the fresh NB media.
Animal model and lesion analysis. In this study, 10-week R6/2 HD tg (The Jackson Laboratory, Bar 
Harbor, ME, U.S.A.), littermate wt, and male C57BL/6J mice (SLC, Inc., Shizuoka, Japan) were used. All pro-
cedures were performed in accordance with guidelines for the care and use of laboratory animals at Yonsei 
University, as approved by the Association for Assessment and Accreditation of Laboratory Animal Care 
(AAALAC). Mice were anesthetized with 2.0% isoflorane under 30% oxygen and 70% nitrous oxide using a 
vaporizer (VMC Anesthesia Machine, MDS matrix; Orchard Park, NY, USA). 3-NP (Sigma, USA) was dissolved 
in saline to a concentration of 0.5 mg per μ l (pH 7.4). The prepared solution of 3-NP was delivered by sustained 
infusion (180 ~ 190 mg/Kg/day) using osmotic minipumps at an infusion rate of 0.5 μ l/h for seven days (1007D; 
Alzet, Cupertino, CA, USA). C1q (Quidel, San Diego, CA, USA) (100 ug/ml, 2 ul) was injected into striatum 
(anterior, 0.7 mm; lateral, 1.2 mm; depth, − 3.3 mm) for 5 min and withdrew the needle after retention for 7 min. 
The degenerated brain region was validated with cresyl violet staining, and magnetic resonance image (MRI) 
analysis. For MRI analysis, we performed MRI scans of mice on a horizontal bore (400 mm) 4.7 Teslar MR scan-
ner (Brucker Biospin, Billerica, MA, USA) after mice were anesthetized with isoflorane. Images were obtained 
using a T2-weighted fast spin echo sequence. Diffusion images were also acquired. Temperature was maintained 
and respiration was monitored throughout the entire scan. Mice recovered quickly following the scan with a 100% 
survival rate. The striatal atrophy was measured as an area of the lateral ventricle.
Behavior and motor function test. The motor functions of the mice were tested with the hindlimb clasp-
ing function. Mice were suspended by their tail and checked whether their hindlimb were clasped or not. The 
accelerating rotarod was performed on a rotarod apparatus (Ugo Basile North America Inc., Schwenksville, PA, 
USA) with speeds that varied from 4 to 40 r.p.m. for a maximum of 5 min. Each mouse was pre-trained prior to 
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the implantation of the osmotic pump filled with 3-NP or saline. The training session was followed by a 30 min 
rest period, after which mice were placed back on the rotarod for five trials of five minutes maximum at acceler-
ating speeds.
qPCR. Total RNA was isolated from mice striatum and cortex. Isolated RNA was purified and its quality deter-
mined by NanoDrop. Total RNA (200 ng) was used in real-time quantitative PCR (qPCR) using a StepOne Plus 
(Applied Biosystems, USA). Reactions were performed in a 20 μ l volume with 2 μ l cDNA, 0.5 μ M primers and 
reagents included in the DNA Master SYBR Green I mix (Roche Diagnostics, Germany). The reaction under-
went pre-incubation step at 95 °C for 5 min, and was amplified by 45 cycles of denaturing at 95 °C for 15 sec and 
annealing and extending at 60 °C for 30 sec. Detection of the fluorescent products was carried out at the end of 
the extension period. GAPDH was amplified as an internal control. To confirm amplification specificity, the PCR 
was performed in no-transcript-control (NTC) and the PCR products from each primer pair were subjected to 
melting curve. Data analyzed by the comparative Ct method. Each gene was analyzed in three biological replicates 
and three technical replicates.
Immunocytochemistry/immunohistochemistry and confocal microscopy. To determine the 
pattern of localization of each molecule, we performed immunofluorescent staining. After sacrificing the mice, 
the brains were removed, postfixed overnight in 3.7% formaldehyde, and stored in 30% sucrose. For cultured 
neuron fixation, neurons on a coverslip fixed with 4% sucrose in 2% PFA for 10 min. After fixation, the brains 
were cut into coronal sections of 20 μ m thickness on a cryostat section and processed for immunohistochem-
istry. Fixed sections were incubated with blocking solution, and incubated with a primary antibody at a dilu-
tion of 1:100. After washing, the sections were incubated with fluorescence-conjugated antibody (1:200; Jackson 
ImmunoResearch, West Grove, PA, USA). For counter-staining, the sections were incubated with DAPI or 
Hoechst 333342 (Molecular Probe, USA). After washing, stained tissue samples were mounted using Vectashield 
(Vector Lab, Burlingame, CA, USA). These sections were then observed under a confocal laser scanning micro-
scope (Carl Zeiss, Thornwood, NY, USA).
Cell death assay. According to manufacturer instructions, apoptosis-related DNA fragmentation assay was 
evaluated using a cytoplasmic histone-associated DNA fragment kit (Roche Diagnostics, USA). We performed 
assay following the manufacturer’s protocol.
Gene s i lencing.  The  ASK1 gene  was  s i l ence d  us ing  s iRNA against  ASK1 ( s ens e , 
GCUCGUAAUUUAUACACUGtt; antisense, CAGUGUAUAAAUUACGAGCtt; conc: 5 μ M; Ambion, Austin, 
TX, USA). The silencing efficiency was confirmed in PC12 culture cells. After confirmation in vitro, the transfect-
ing reagent, SiPORT NeoFX (Ambion), and ASK1-siRNA or nonfunctional mutant RNA (control siRNA, 5′ -AAG 
AGA AAA AGC GAA GAG CCA-3′ ; Ambion) were combined, mixed gently, and allowed to form siRNA lipos-
omes for an additional 10 min at room temperature. A micro-osmotic pump (Alzet, USA), containing 100 μ l of 
the transfection reagent only or ASK1-siRNA was then placed subcutaneously on the backs of the mice and a 
brain infusion cannula connected to a pump was positioned at the intra-striatum. The designated solution was 
infused for seven days at a rate of 0.5 μ L/h during 3-NP infusion. The mice were killed seven days after surgery 
and their brains were processed. In case of primary neuron, siRNA was tansfected at 12 DIV and collected at 
15 DIV after incubating for 72 hours.
Astrocyte conditioned medium. To test the effect of astrocyte derived unknown factor on neu-
ron, we used astrocyte (C8-D1A) which was purchased from American Type Culture Collection (ATCC, 
Manassas, VA, USA). Astrocytes were cultured in Dulbecco’s Modified Eagle’s Medium high glucose (DMEM, 
Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS, Invitrogen, USA) and 1% 
penicillin-streptomycin solution (Thermo Scientific, Waltham, MA, USA). The cultures were maintained at 37 °C 
in a humidified CO2 incubator. For obtaining astrocyte conditioned medium (ACM), confluent astrocyte cell 
cultures were washed and replaced with serum-free medium DMEM/F12 (Thermo Scientific, USA) without FBS 
(Invitrogen, USA). Astrocytes in serum-free media were exposed to 1 mM 3-NP for 4 h and 24 h each. After then, 
media were collected and removed cell debris by centrifuging at 1,000 g × 10 min. To evaluate the effect of ACM 
on neurons, primary neurons were cultured in Neurobasal media (Invitrogen, USA). At 15 DIV, neurons were 
replaced with ACM exposed to 3-NP and incubated additionally 4 h. Effects of ACM on neuron were assessed by 
immunocytochemistry of PSD95.
To further evaluate whether TGF-β 1 of ACM mainly affected on neuron and synaptic dysfunction, ACM was 
incubate with 1 μ g/mL TGF-β 1 antibody (Abcam, Cambridge, MA, USA) for 30 min at room temperature to 
deplete TGF-β 1 from ACM by neutralizing the TGF-β 1. ACM neutralizing TGF-β 1 was also treated on neuron 
for 4 h and neuronal changes were observed. According to the manufacturer’s information, TGF-β 1 is neutralized 
50% of the bioactivity when 0.25 μ g/mL TGF-β 1 antibody was treated in HT2 cell line.
ELISA. The samples for ELISA were prepared in animal blood serum and culture media. Prepared samples 
were performed according to the manufacturer’s provided protocol. Standards were diluted with each assay buffer 
provided. Each assay was followed with each procedure. ELISA kits were obtained for total TGF-β 1 (BioLegend, 
San Diego, CA, USA) and mouse C1q (Hycult Biotech, Uden, Netherlands).
Statistical analysis. Data are expressed as mean ± SD. The significance of differences among multiple 
groups was evaluated by ANOVA followed by Bonferroni’s post hoc protected least-significant difference test 
while two groups were compared using unpaired t tests (SigmaStat, Systat Software Inc, San Jose, CA, USA).
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